Glycation of apolipoprotein E impairs its binding to heparin: Identification of the major glycation site

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1454, Issue 3, 1999, Pages 296-308

  Shuvaev, Vladimir V ^a,b   Fujii, Junichi ^a   Kawasaki, Yoshimi ^a   Itoh, Hidehiko ^c   Hamaoka, Rieko ^a   Barbier, Anne ^b   Ziegler, Olivier ^d   Siest, Gérard ^b   Taniguchi, Naoyuki ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Centre du Medicament URA CNRS 597   (France)

^c Ikeda Municipal Hospital   (Japan)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Apolipoprotein E; Diabetes; Glycation; Heparin binding activity

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN E; HEPARIN; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCATION; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; IMMUNOBLOTTING; IN VITRO STUDY; LIPID ANALYSIS; LIPID METABOLISM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING;

AGED; APOLIPOPROTEINS E; BINDING SITES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCOSE; GLYCOSYLATION; HEPARIN; HUMANS; HYPERGLYCEMIA; LIPOPROTEINS, VLDL; LYSINE; MASS SPECTROMETRY; PEPTIDE FRAGMENTS; SERINE ENDOPEPTIDASES; SURFACE PLASMON RESONANCE;

EID: 0032813440     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4439(99)00047-2     Document Type: Article

References (55)

1. Bierman E.L. Atherogenesis in diabetes. Arterioscler. Thromb. 12:1992;647-656.
2. O'Brien R., Timmins K. The role of oxidation and glycation in the pathogenesis of diabetic atherosclerosis. Trends Endocrinol. Metab. 5:1994;329-334.
3. Guerci B., Ziegler O., Drouin P. Hyperlipidemia during diabetes mellitus. Recent developments. Presse Med. 23:1994;82-88.
4. Schonfeld G., Birge C., Miller J.P., Kessler G., Santiago J. Apolipoprotein B levels and altered lipoprotein composition in diabetes. Diabetes. 23:1974;827-834.
5. Gabor J., Spain M., Kalant N. Composition of serum very-low-density and high-density lipoproteins in diabetes. Clin. Chem. 26:1980;1261-1269.
6. Yegin A., Ozben T., Yegin H. Glycation of lipoproteins and accelerated atherosclerosis in non-insulin-dependent diabetes mellitus. Int. J. Clin. Lab. Res. 25:1995;157-161.
7. Bucala R., Makita Z., Vega G., Grundy S., Koschinsky T., Cerami A., Vlassara H. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc. Natl. Acad. Sci. USA. 91:1994;9441-9445.
8. Colaco C.A., Roser B.J. Atherosclerosis and glycation. BioEssays. 16:1994;145-147.
9. Curtiss L.K., Witztum J.L. A novel method for generating region-specific monoclonal antibodies to modified proteins. Application to the identification of human glucosylated low density lipoproteins. J. Clin. Invest. 72:1983;1427-1438.
10. Curtiss L.K., Witztum J.L. Plasma apolipoproteins AI, AII, B, CI, and E are glucosylated in hyperglycemic diabetic subjects. Diabetes. 34:1985;452-461.
11. Panteghini M., Bonora R., Pagani F. Determination of glycated apolipoprotein B in serum by a combination of affinity chromatography and immunonephelometry. Ann. Clin. Biochem. 31:1994;544-549.
12. Kortlandt W., van Rijn H.J.M., Erkelens D.W. Glycation and lipoproteins. Diabetes Nutr. Metab. 6:1993;231-239.
13. Gugliucci-Creriche A., Stahl A.J.C. Glycation and oxidation of human low density lipoproteins reduces heparin binding and modifies charge. Scand. J. Clin. Lab. Invest. 53:1993;125-132.
14. Calvo C., Talussot C., Ponsin G., Berthezene F. Non enzymatic glycation of apolipoprotein A-I. Effects on its self-association and lipid binding properties. Biochem. Biophys. Res. Commun. 153:1988;1060-1067.
15. Calvo C., Verdugo C. Association in vivo of glycated apolipoprotein A-I with high density lipoproteins. Eur. J. Clin. Chem. Clin. Biochem. 30:1992;3-5.
16. Calvo C., Ulloa N., Del Pozo R., Verdugo C. Decreased activation of lecithin:cholesterol acyltransferase by glycated apolipoprotein A-I. Eur. J. Clin. Chem. Clin. Biochem. 31:1993;217-220.
17. Duell P.B., Oram J.F., Bierman E.L. Nonenzymatic glycosylation of HDL resulting in inhibition of high-affinity binding to cultured human fibroblasts. Diabetes. 39:1990;1257-1263.
18. Duell P.B., Oram J.F., Bierman E.L. Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes. 40:1991;377-384.
19. Mamo J.C.L., Szeto L., Steiner G. Glycation of very low density lipoprotein from rat plasma impairs its catabolism. Diabetologia. 33:1990;339-345.
20. Yamamoto M., Ranganathan S., Kottke B.A. Metabolism of glycosylated very-low-density lipoproteins in human skin fibroblasts. Biochim. Biophys. Acta. 875:1986;410-413.
21. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240:1988;622-630.
22. Weisgraber K.H., Apolipoprotein E. Structure-function relationships. Adv. Protein Chem. 45:1994;249-302.
23. Mahley R.W., Hussain M.M. Apolipoprotein E: impact of cytoskeletal stability in neurons and the relationship to Alzheimer's disease. Curr. Opin. Lipidol. 2:1991;170-176.
24. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90:1993;1977-1981.
25. Shuvaev V.V., Siest G. Interaction between human amphipathic apolipoproteins and amyloid beta-peptide: surface plasmon resonance studies. FEBS Lett. 383:1996;9-12.
26. Golabek A.A., Soto C., Vogel T., Wisniewski T. The interaction between apolipoprotein E and Alzheimer's amyloid beta-peptide is dependent on β-peptide conformation. J. Biol. Chem. 271:1996;10602-10606.
27. Eto M., Chait A., Bierman E.L. Postprandial remnant-rich lipoprotein fractions from Type 2 diabetics (NIDDM) enhance incorporation of 14-C oleate into cholesteryl esters in human macrophages. Arteriosclerosis. 10:1990;787a.
28. Gregg R.E., Zech L.A., Schaefer E.J., Stark D., Wilson D., Brewer H.B. Jr. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J. Clin. Invest. 78:1986;815-821.
29. Jönsson U., Fägerstam L., Ivarsson B., Johnsson B., Karlsson R., Lundh K., Löfas S., Persson B., Roos H., Ronnberg I., Sjolander S., Stenberg E., Stahlberg S., Urbaniczky C., Ostlin H., Malmqvist M. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques. 11:1991;620-627.
30. Malmqvist M. Biospecific interaction analysis using biosensor technology. Nature. 361:1993;186-187.
31. Barbier A., Visvikis A., Mathieu F., Diez L., Havekes L.M., Siest G. Characterization of three human apolipoprotein E isoforms (E2, E3 and E4) expressed in Escherichia coli. Eur. J. Clin. Chem. Clin. Biochem. 35:1997;581-589.
32. Weisgraber K.H., Rall S.C., Mahley R.W. Human apoE heterogeneity. Cys-Arg interchanges in the amino acid sequence of apoE isoform. J. Biol. Chem. 256:1981;9077-9083.
33. Myint T., Hoshi S., Ookawara T., Miyazawa N., Suzuki K., Taniguchi N. Immunological detection of glycated proteins in normal and streptozotocin-induced diabetic rats using anti hexitol-lysine IgG. Biochim. Biophys. Acta. 1272:1995;73-79.
34. Foxall C., Holme K.R., Liang W., Wei Z. An enzyme-linked immunosorbent assay using biotinylated heparan sulfate to evaluate the interactions of heparin-like molecules and basic fibroblast growth factor. Anal. Biochem. 231:1995;366-373.
35. Takahashi M., Lu Y., Myint T., Fujii J., Wada Y., Taniguchi N. In vivo glycation of aldehyde reductase, a major 3-deoxyglucosone reducing enzyme: identification of glycation sites. Biochemistry. 34:1995;1433-1438.
36. Garcia M.J., McNamara P.M., Gordon T., Kannel W.B. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes. 23:1974;105-111.
37. Wagner J.D., Bagdade J.D., Litwak K.N., Zhang L., Bell-Farrow A.D., Wang Z.Q., Cefalu W.T. Increased glycation of plasma lipoproteins in diabetic cynomolgus monkeys. Lab. Anim. Sci. 46:1996;31-35.
38. Feussner G., Scharnagl H., Scherbaum C., Acar J., Dobmeyer J., Lohrmann J., Wieland H., Marz W. Apolipoprotein E5 (Glu212→Lys): increased binding to cell surface proteoglycans but decreased uptake and lysosomal degradation in cultured fibroblasts. J. Lipid Res. 37:1996;1632-1645.
39. Yamamura T., Dong L.M., Yamamoto A. Characterization of apolipoprotein E7 (Glu244→Lys, Glu245→Lys), a mutant apolipoprotein E associated with hyperlipidemia and atherosclerosis. J. Lipid Res. 40:1999;253-259.
40. Mann W.A., Meyer N., Weber W., Meyer S., Greten H., Beisiegel U. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia. J. Lipid Res. 36:1995;517-525.
41. Cardin A.D., Demeter D.A., Weintraub H.J., Jackson R.L. Molecular design and modeling of protein-heparin interactions. Methods Enzymol. 203:1991;556-583.
42. Mahley R.W., Ji Z.S. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40:1999;1-16.
43. Fuki I.V., Kuhn K.M., Lomazov I.R., Rothman V.L., Tuszynski G.P., Iozzo R.V., Swenson T.L., Fisher E.A., Williams K.J. The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J. Clin. Invest. 100:1997;1611-1622.
44. Al-Haideri M., Goldberg I.J., Galeano N.F., Gleeson A., Vogel T., Gorecki M., Sturley S.L., Deckelbaum R.J. Heparan sulfate proteoglycan-mediated uptake of apolipoprotein E-triglyceride-rich lipoprotein particles: a major pathway at physiological particle concentrations. Biochemistry. 36:1997;12766-12772.
45. Vogel T., Guo N.G., Guy R., Drezlich N., Krutzsch H.C., Blake D.A., Panet A., Roberts D.D. Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. J. Cell. Biochem. 54:1994;299-308.
46. Clay M.A., Anantharamaiah G.M., Mistry M.J., Balasubramaniam A., Harmony J.A.K. Localization of a domain in apolipoprotein E with both cytostatic and cytotoxic activity. Biochemistry. 34:1995;11142-11151.
47. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.M., Salvesen G.S., Pericak-Vance M., Schmechel D., Saunders A.M., Goldgaber D., Roses A.D. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90:1993;8098-8102.
48. Small G.W., Rosenthal M.J. Coexistence of Alzheimer's disease and diabetes mellitus. J. Am. Geriatr. Soc. 40:1992;1075-1076.
49. Curb J.D., Rodriguez B.L., Abbott R.D., Petrovitch H., Ross G.W., Masaki K.H., Foley D., Blanchette P.L., Harris T., Chen R., White L.R. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology. 52:1999;971-975.
50. Calvo C., Ulloa N., Campos M., Verdugo C., Ayrault-Jarrier M. The preferential site of non-enzymatic glycation of human apolipoprotein A-I in vivo. Clin. Chim. Acta. 217:1993;193-198.
51. Bucala R., Mitchell R., Arnold K., Innerarity T., Vlassara H., Cerami A. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J. Biol. Chem. 270:1995;10828-10832.
52. Mahley R.W., Innerarity T.L., Rall S.C., Weisgraber K.H. Plasma lipoproteins: apolipoprotein structure and function. J. Lipid Res. 25:1984;1277-1294.
53. Iberg N., Fluckiger R. Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J. Biol. Chem. 261:1986;13542-13545.
54. Cardin A.D., Hirose N., Blankenship D.T., Jackson R.L., Harmony A.K. Binding of a high reactive heparin to human apolipoprotein E: identification of two heparin-binding domains. Biochem. Biophys. Res. Commun. 134:1986;783-789.
55. Weisgraber K.H., Rall S.C., Mahley R.W., Milne R.W., Marcel L., Sparrow J.T. Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. J. Biol. Chem. 261:1986;2068-2076.